ArticleInvestigative ophthalmology & visual science2025
Dualistic Role of MITF in Uveal Melanoma: Defining Two Distinct Cellular Subpopulations With Prognostic and Therapeutic Implications.
Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Research progress on the mechanisms of Panax ginseng and its active components in maintaining skin homeostasis and disease intervention.Chinese medicine · 2026Review
- Canine melanomas: MiTF and p38 expression and its correlation with the presence of lymphocytic infiltrate, proliferation, and survival.Veterinary research communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Microphthalmia-associated transcription factor (MITF) regulates melanocyte differentiation, proliferation, and survival, intersecting with oncogenic and tumor-suppressive pathways. However, its prognostic significance in uveal melanoma (UM) remains unexplored in large cohorts. This study examines MITF's prognostic value and its correlation with key molecular markers-BAP1, preferentially expressed antigen in melanoma (PRAME), deoxythymidylate kinase (dTYMK), and poly(ADP-ribose) polymerase 1 (PARP1). Methods: Immunostaining for MITF, BAP1, dTYMK, PARP1, and PRAME was performed on tissue microarrays from 154 UM cases with no prior therapy. We correlated MITF level with detailed clinicopathologic variables and patient outcomes. Scoring of MITF immunostainings was done using the H-score with further dichotomization into two subgroups with low (H-score < 15) and high level (H-score ≥ 15) using the Contal-O'Quinley method. Results: Patients with low MITF level were characterized by shorter cancer-specific overall (P = 0.019) and disease-free survival (P = 0.0038). Low MITF level was significantly correlated with the presence of distant metastases (P = 0.005), BAP1-negative tumors (P = 0.023), higher largest basal diameter (P < 0.001), and tumor-associated macrophages immune response (P < 0.001). On the other hand, high MITF level was correlated with a higher mitotic index (P = 0.033) and enhanced replicating potential of tumoral cells significantly correlated with dTYMK and PARP1 level (P < 0.001). Conclusions: MITF delineates two UM subpopulations: (1) MITF-low tumors-slow proliferators with high invasive potential and inflammatory phenotype, and (2) MITF-high tumors-rapidly dividing cells with lower invasiveness and immunosuppressive properties. These findings suggest potential therapeutic strategies, including MITF re-induction for MITF-low tumors and dTYMK/PARP1 inhibitors for MITF-high UM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.